Swiss bio Addex halts Parkinson's test as trial delays tick up on COVID-19 disruption

Addex Therapeutics has seen its shares down 15% on the news that it has had to delay a registrational study of its Parkinson’s disease candidate.

The trial, known as study 301, was of dipraglurant to treat levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). The company says it has “been postponed” with no timelines in place for its restart because of the continued spread of COVID-19 in Europe, now the epicenter of the pandemic.